Anebulo Pharmaceuticals Analyst Ratings
Anebulo Pharmaceuticals Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/03/2023 | 154.78% | Benchmark | → $8 | Reiterates | Speculative Buy → Speculative Buy |
| 09/25/2023 | 91.08% | HC Wainwright & Co. | → $6 | Reiterates | Buy → Buy |
| 09/21/2023 | 91.08% | Maxim Group | → $6 | Initiates Coverage On | → Buy |
| 09/18/2023 | 91.08% | HC Wainwright & Co. | → $6 | Initiates Coverage On | → Buy |
| 05/18/2023 | 154.78% | Benchmark | → $8 | Reiterates | Speculative Buy → Speculative Buy |
| 02/14/2023 | 154.78% | Benchmark | $10 → $8 | Maintains | Speculative Buy |
| 07/27/2022 | 91.08% | Ladenburg Thalmann | → $6 | Initiates Coverage On | → Buy |
| 05/25/2021 | 377.71% | Benchmark | → $15 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 10/03/2023 | 154.78% | 基准 | →$8 | 重申 | 投机性买入→投机性买入 |
| 09/25/2023 | 91.08% | HC Wainwright公司 | →$6 | 重申 | 购买→购买 |
| 2023年09月21日 | 91.08% | Maxim集团 | →$6 | 开始承保 | →购买 |
| 09/18/2023 | 91.08% | HC Wainwright公司 | →$6 | 开始承保 | →购买 |
| 2023年05月18日 | 154.78% | 基准 | →$8 | 重申 | 投机性买入→投机性买入 |
| 02/14/2023 | 154.78% | 基准 | $10→$8 | 维护 | 投机性购买 |
| 07/27/2022 | 91.08% | 拉登堡·塔尔曼 | →$6 | 开始承保 | →购买 |
| 2021/05/25 | 377.71% | 基准 | →$15 | 开始承保 | →购买 |
What is the target price for Anebulo Pharmaceuticals (ANEB)?
AneBulo制药公司(ANEB)的目标价是多少？
The latest price target for Anebulo Pharmaceuticals (NASDAQ: ANEB) was reported by Benchmark on October 3, 2023. The analyst firm set a price target for $8.00 expecting ANEB to rise to within 12 months (a possible 154.78% upside). 6 analyst firms have reported ratings in the last year.
安妮宝制药(纳斯达克：ANEB)的最新目标价是由Benchmark于2023年10月3日报道的。这家分析公司将目标价定为8美元，预计ANEB将在12个月内上涨至(可能上涨154.78%)。6家分析公司在过去一年公布了评级。
What is the most recent analyst rating for Anebulo Pharmaceuticals (ANEB)?
分析师对安妮宝制药(ANEB)的最新评级是多少？
The latest analyst rating for Anebulo Pharmaceuticals (NASDAQ: ANEB) was provided by Benchmark, and Anebulo Pharmaceuticals reiterated their speculative buy rating.
纳斯达克(Sequoia Capital：ANEB)的最新分析师评级由Benchmark提供，AneBulo PharmPharmticals重申其投机性买入评级。
When is the next analyst rating going to be posted or updated for Anebulo Pharmaceuticals (ANEB)?
AneBulo PharmPharmticals(ANEB)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Anebulo Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Anebulo Pharmaceuticals was filed on October 3, 2023 so you should expect the next rating to be made available sometime around October 3, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与AneBulo制药公司的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。AneBulo制药的上一次评级是在2023年10月3日提交的，所以你应该预计下一次评级将在2024年10月3日左右的某个时候公布。
Is the Analyst Rating Anebulo Pharmaceuticals (ANEB) correct?
分析师对AneBulo制药公司(ANEB)的评级正确吗？
While ratings are subjective and will change, the latest Anebulo Pharmaceuticals (ANEB) rating was a reiterated with a price target of $0.00 to $8.00. The current price Anebulo Pharmaceuticals (ANEB) is trading at is $3.14, which is within the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的AneBulo制药(ANEB)评级被重申，目标价在0.00美元至8.00美元之间。AneBulo PharmPharmticals(ANEB)目前的交易价格为3.14美元，在分析师的预测范围内。